<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>TNF inhibitors for inflammatory arthritis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">TNF inhibitors for inflammatory arthritis</h1>
<div class="graphic"><div class="figure"><div class="ttl">TNF inhibitors for inflammatory arthritis</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup><colgroup span="2" width="30%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug</td> <td class="subtitle1">Route of administration</td> <td class="subtitle1">Typical starting dose</td> <td class="subtitle1">Notes</td> </tr> <tr> <td>Etanercept</td> <td>SUBQ</td> <td>50 mg SUBQ once weekly</td> <td>For concurrent moderate to severe plaque psoriasis – Start with etanercept 50 mg twice weekly for 3 months</td> </tr> <tr class="highlight_lght_gray_text"> <td rowspan="2">Infliximab</td> <td>IV</td> <td>5 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks</td> <td rowspan="2"> <p>Administration with a conventional DMARD (eg, methotrexate) promotes drug survival</p> In the United States, SUBQ administration is approved only for ulcerative colitis and Crohn disease, and induction strategy differs; refer to local prescribing information for additional information including approved uses</td> </tr> <tr class="highlight_lght_gray_text"> <td>SUBQ<sup>[1,2]</sup></td> <td> <p>SUBQ induction – 120 mg SUBQ once weekly for 5 doses (ie, weeks 0, 1, 2, 3, 4), then 120 mg SUBQ once every 2 weeks</p> IV induction – 3 mg/kg IV at 0 and 2 weeks, then 120 mg SUBQ every 2 weeks starting 4 weeks after the second IV dose</td> </tr> <tr> <td>Adalimumab</td> <td>SUBQ</td> <td>40 mg SUBQ every other week</td> <td>Administration with a conventional DMARD (eg, methotrexate) promotes drug survival</td> </tr> <tr class="highlight_lght_gray_text"> <td>Certolizumab pegol</td> <td>SUBQ</td> <td>400 mg SUBQ at 0, 2, and 4 weeks, followed by 200 mg every other week</td> <td>PEGylation prevents crossing the placenta</td> </tr> <tr> <td rowspan="2">Golimumab</td> <td>SUBQ</td> <td>50 mg SUBQ once a month</td> <td rowspan="2">Available in both SUBQ and IV formulations</td> </tr> <tr> <td>IV</td> <td>2 mg/kg IV at weeks 0 and 4, then every 8 weeks</td> </tr> </tbody></table></div><div class="graphic_lgnd">Choice of TNF inhibitor depends upon patient factors such as comorbidities and patient preferences (eg, for route of administration and frequency of treatment) and regulatory or insurance restrictions on drug choice. Biosimilar agents for some TNF inhibitors are available and may be less costly; refer to local product availability.</div><div class="graphic_footnotes">DMARD: disease-modifying antirheumatic drug; IV: intravenously; PEG: polyethylene glycol; SUBQ: subcutaneously; TNF: tumor necrosis factor.</div><div class="graphic_reference">References:
<ol>
<li>Infliximab. Health Canada-approved product monograph. Revised March 7, 2023. Health Canada. <a href="https://health-products.canada.ca/dpd-bdpp/index-eng.jsp" target="_blank">https://health-products.canada.ca/dpd-bdpp/index-eng.jsp</a> (Accessed on January 5, 2024).</li>
<li>Infliximab. European Medicines Agency (EMA) summary of product characteristics. Last updated June 10, 2023. European Medicines Agency. www.ema.europa.eu/en/medicines (Accessed on January 5, 2024).</li>
</ol>
<p class="extra_spacing_top">With additional data from:</p>
<ol>
<li>Lexicomp online. Copyright © 1978-2024 by Lexicomp, Inc. All rights reserved.</li>
</ol></div><div id="graphicVersion">Graphic 143868 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
